Filing Flows › AbCellera Biologics (ABCL) › Q1 2025
AbCellera Biologics (ABCL) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
AbCellera Biologics (ABCL) reported revenue of $4.2M for the first quarter 2025 (Q1 2025), -57% from a year earlier and -16% from the quarter before.
AbCellera Biologics, Q1 2025: revenue $4.2M (-58% year over year), net loss $45.6M, operating cash flow −$11.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.2M | -16% | -57% |
| Operating profit | −$62.7M | — | — |
| Net earnings | −$45.6M | — | — |
| Operating cash flow | −$11.6M | — | — |
What changed
Revenue was $4.2M in Q1 2025, down 57% year over year and down 16% from the previous quarter. Research fees was the largest line at 96% of revenue. Research fees lost $5.7M year over year (down 58%), 100% of the total change.
Operating costs exceeded revenue by $62.7M, an operating margin of -1479.6%. Total costs grew 3% against a revenue fall of 57%. The fastest-growing cost line was Other operating costs (+10%). The quarter ended with a net loss of $45.6M, wider than the previous quarter's $34.2M loss.
Operating cash flow was −$11.6M. Non-cash charges added back $5.3M of depreciation and amortization and $14.8M of share-based compensation. Working capital and other items added $13.9M. Capital expenditures of $10.6M exceeded it, leaving free cash flow of −$22.2M.
Questions
What was AbCellera Biologics' revenue in the first quarter 2025?
AbCellera Biologics (ABCL) reported revenue of $4.2M for the first quarter 2025 (Q1 2025), -57% from a year earlier and -16% from the quarter before.